September 30, 2021 07:22 AM EDT
People

SEC charges ex-Gold­man Sachs an­a­lyst with il­le­gal­ly prof­it­ing off bio­phar­ma merg­ers in in­sid­er trad­ing scheme

Max Gelman

Senior Editor

A for­mer com­pli­ance an­a­lyst abused his ac­cess to con­fi­den­tial and non-pub­lic in­for­ma­tion to il­le­gal­ly prof­it off of dozens of merg­ers and SPAC deals, in­clud­ing sev­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times